pilocarpine has been researched along with Presbyopia in 16 studies
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
(+)-pilocarpine : The (+)-enantiomer of pilocarpine.
Presbyopia: The normal decreasing elasticity of the crystalline lens that leads to loss of accommodation.
Excerpt | Relevance | Reference |
---|---|---|
"To present a case series of retinal detachments associated with the use of pilocarpine for presbyopia." | 8.12 | Retinal Detachments Associated With Topical Pilocarpine Use for Presbyopia. ( Al-Khersan, H; Flynn, HW; Townsend, JH, 2022) |
"Pilocarpine plasma levels were assessed in approximately 10% of enrolled participants." | 7.30 | Safety and Efficacy of Twice-Daily Pilocarpine HCl in Presbyopia: The Virgo Phase 3, Randomized, Double-Masked, Controlled Study. ( El-Harazi, SM; Kannarr, S; Kim, JL; Lievens, C; Liu, H; Moshirfar, M; Peace, JH; Robinson, MR; Safyan, E; Zheng, S, 2023) |
"This special commentary reviews the treatment of presbyopia with a focus on the recently approved medication Vuity (pilocarpine 1." | 6.82 | Pilocarpine 1.25% and the changing landscape of presbyopia treatment. ( Ho, AC; Lee, JK; Meghpara, BB; Mian, SI; Rapuano, CJ, 2022) |
"To present a case series of retinal detachments associated with the use of pilocarpine for presbyopia." | 4.12 | Retinal Detachments Associated With Topical Pilocarpine Use for Presbyopia. ( Al-Khersan, H; Flynn, HW; Townsend, JH, 2022) |
" Safety measures included adverse events." | 3.11 | Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial. ( Gore, A; Guo, Q; Liu, H; McCabe, C; Moshirfar, M; Price, FW; Robinson, MR; Safyan, E; Waring, GO; Wirta, D, 2022) |
"This special commentary reviews the treatment of presbyopia with a focus on the recently approved medication Vuity (pilocarpine 1." | 2.82 | Pilocarpine 1.25% and the changing landscape of presbyopia treatment. ( Ho, AC; Lee, JK; Meghpara, BB; Mian, SI; Rapuano, CJ, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (18.75) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 9 (56.25) | 2.80 |
Authors | Studies |
---|---|
Waring, GO | 1 |
Price, FW | 1 |
Wirta, D | 1 |
McCabe, C | 1 |
Moshirfar, M | 2 |
Guo, Q | 1 |
Gore, A | 1 |
Liu, H | 2 |
Safyan, E | 2 |
Robinson, MR | 2 |
Al-Khersan, H | 1 |
Flynn, HW | 1 |
Townsend, JH | 1 |
Meghpara, BB | 1 |
Lee, JK | 1 |
Rapuano, CJ | 1 |
Mian, SI | 1 |
Ho, AC | 1 |
Westheimer, G | 1 |
Amarikwa, L | 1 |
Michalak, SM | 1 |
Caul, S | 1 |
Mruthyunjaya, P | 1 |
Rahimy, E | 1 |
Mansoori, T | 1 |
Kannarr, S | 1 |
El-Harazi, SM | 1 |
Lievens, C | 1 |
Kim, JL | 1 |
Peace, JH | 1 |
Zheng, S | 1 |
Tucker, T | 1 |
Early, J | 1 |
Ostrin, LA | 1 |
Glasser, A | 2 |
Koeppl, C | 1 |
Findl, O | 1 |
Kriechbaum, K | 1 |
Drexler, W | 1 |
Liu, DT | 1 |
Hon, C | 1 |
Lam, DS | 1 |
Chan, WM | 1 |
Wendt, M | 1 |
Croft, MA | 1 |
McDonald, J | 1 |
Kaufman, PL | 1 |
Abramson, DH | 1 |
Franzen, LA | 1 |
Coleman, DJ | 1 |
Ichikawa, H | 1 |
Suzumura, A | 1 |
Taniguchi, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Participants With Presbyopia[NCT03804268] | Phase 3 | 323 participants (Actual) | Interventional | 2018-12-21 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Visual acuity for near (40 cm) target was measured in mesopic conditions. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. MMRM was used for analyses. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 0.25)
Intervention | letters correctly read (Least Squares Mean) |
---|---|
Vehicle | 3.7 |
Pilocarpine HCl Ophthalmic Solution | 6.3 |
Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. Mixed effect model for repeated measures (MMRM) was used for analyses. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 0.5)
Intervention | letters read correctly (Least Squares Mean) |
---|---|
Vehicle | 4.2 |
Pilocarpine HCl Ophthalmic Solution | 9.3 |
Visual acuity for intermediate (66 cm) target was measured in photopic conditions using an eye chart. Photopic condition was defined as high lighting ≥80 cd/m^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. MMRM was used for analyses. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)
Intervention | letters read correctly (Least Squares Mean) |
---|---|
Vehicle | 3.1 |
Pilocarpine HCl Ophthalmic Solution | 6.6 |
NVPTQ had 12 questions on 4 reading tasks(reading a paragraph from book, excerpts from an article in newspaper, portion of a nutrition label, and a section from restaurant menu). Participants completed specific reading tasks under mesopic conditions without any near-vision correction and answered 3 questions for each task, rating their vision-related reading ability as 0=I could not read any text due to problems seeing up close,1=poor,2=fair,3=good,4=very good,5=excellent;impact of squinting on performance as 0=No,I did not squint, 1=Yes,squinting helped me read some/all text, 2=Yes,but I still could not read any of the text; and satisfaction as 0=very dissatisfied to 4=very satisfied. The score based on vision related ability and impact of squinting=(Book testlet+Newspaper testlet+Menu testlet+Nutrition Label testlet)/(testlets with non-missing responses), total possible score of 0-5. Higher scores=better outcomes;positive change from Baseline=improved performance(reading ability). (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Vehicle | 0.6 |
Pilocarpine HCl Ophthalmic Solution | 1.4 |
NVPTQ had 12 questions on 4 reading tasks(reading a paragraph from book, excerpts from an article in newspaper, portion of a nutrition label, and a section from restaurant menu). Participants completed specific reading tasks under mesopic conditions without any near-vision correction and answered 3 questions for each task, rating their vision-related reading ability as 0=I could not read any text due to problems seeing up close to 5=excellent; impact of squinting on performance as 0=No, I did not squint, 1=Yes, squinting helped me read some/all text, 2=Yes, but I still could not read any of the text; and satisfaction as 0=very dissatisfied,1=dissatisfied,2=neither satisfied nor dissatisfied,3=satisfied, 4=very satisfied. The score based on satisfaction items=(Book testlet+Newspaper testlet+Menu testlet+Nutrition Label testlet)/(testlets with non-missing responses) for a total possible score of 0 to 4. Higher scores=better outcomes; a positive change from Baseline=higher satisfaction. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Vehicle | 0.6 |
Pilocarpine HCl Ophthalmic Solution | 1.4 |
PICQ had 20 questions about impact experienced by participants due to their problems seeing up over past 7 days. PICQ Impact domain had 6 items: Item 9:Rely on others,15:rest eyes,16:Feel older,17:Feel self-conscious,19:Take longer to complete a task,20:Inconvenient. First 5 impacts items included response categories: 0=never to 4=all the time. Item 20 had response categories: 0=not at all to 4=extremely. Item 9 included an additional response category with a value of 9 to indicate question was not applicable to participant and the responses were assigned missing values. PICQ Impacts Score=[(Item9+Item15+Items16,17Testlet+Item19+Item20)/(nonmissing responses to 5 components of impacts score)] where Items 16,17 Testlet=(Item16+Item17)/non-missing responses to Items 16 and 17. PICQ Impact score ranges from 0 to 4; with 0=least amount of impacts to 4=greatest amount of impacts. Higher scores correspond to poorer outcomes. A negative change from Baseline=improvement. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Vehicle | -0.4 |
Pilocarpine HCl Ophthalmic Solution | -0.7 |
PICQ=20 questions about impact experienced by participants due to their problems over past 7 days.PICQ Coping domain had 8 items: 1:Normal-sized text,2:Small-sized text,3:Information on a computer,4:Information on a cell phone,5:Increase font size,6:Use glasses to read close,12:Hold reading materials farther out/closer,13:Squint to read. Each item had response categories:0=never to 4=all the time. Items 3, 4, 5, and 6 had additional response categories with values of 9/10 to indicate the question is not applicable to participant and were assigned missing values.PICQ Coping Score:(Item 1,2 Testlet+Item 3,4 Testlet+Item 5+Item 6+Item 12+Item 13)/non-missing responses to the 6 components of coping score where Items 1,2 Testlet=(Item1+Item2)/non-missing responses to Items 1,2;Items 3,4 Testlet=(Item3+Item4)/non-missing responses to Items 3, 4. Score ranges:0=to least amount of coping to 4=greatest amount of coping. Higher scores=poorer outcome; a negative change from Baseline=improvement. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)
Intervention | score on a scale (Least Squares Mean) |
---|---|
Vehicle | -0.5 |
Pilocarpine HCl Ophthalmic Solution | -1.0 |
Visual acuity for near (40 cm) target was measured in photopic conditions using an eye chart. Photopic condition was defined as high lighting ≥80 cd/m^2 measured at the target. Percentage of participants achieving 20/40 or better in photopic, high-contrast, binocular, DCNVA are reported. (NCT03804268)
Timeframe: Day 30 (Hour 1)
Intervention | percentage of participants (Number) |
---|---|
Vehicle | 73.9 |
Pilocarpine HCl Ophthalmic Solution | 92.5 |
Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Photopic condition was defined as high lighting ≥80 cd/m^2 measured at the target. Percentage of participants achieving 20/40 or better in photopic, high-contrast, binocular, DCNVA are reported. (NCT03804268)
Timeframe: Day 30 (Hour 3)
Intervention | percentage of participants (Number) |
---|---|
Vehicle | 71.9 |
Pilocarpine HCl Ophthalmic Solution | 84.5 |
Visual acuity for near (40 centimeters (cm)) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter (cd/m^2) measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)
Intervention | percentage of participants (Number) |
---|---|
Vehicle | 8.1 |
Pilocarpine HCl Ophthalmic Solution | 30.7 |
Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 6)
Intervention | percentage of participants (Number) |
---|---|
Vehicle | 8.8 |
Pilocarpine HCl Ophthalmic Solution | 18.4 |
Visual acuity for near (40cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m^2measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast, binocular DCNVA are reported. (NCT03804268)
Timeframe: Baseline (Day1) to Day 30 (Hour 10)
Intervention | percentage of participants (Number) |
---|---|
Vehicle | 8.6 |
Pilocarpine HCl Ophthalmic Solution | 7.5 |
Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 8)
Intervention | percentage of participants (Number) |
---|---|
Vehicle | 8.5 |
Pilocarpine HCl Ophthalmic Solution | 10.6 |
1 review available for pilocarpine and Presbyopia
Article | Year |
---|---|
Pilocarpine 1.25% and the changing landscape of presbyopia treatment.
Topics: Humans; Myopia; Pilocarpine; Presbyopia; Vision, Ocular | 2022 |
3 trials available for pilocarpine and Presbyopia
Article | Year |
---|---|
Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial.
Topics: Color Vision; Female; Humans; Male; Pilocarpine; Presbyopia; Treatment Outcome; Visual Acuity | 2022 |
Safety and Efficacy of Twice-Daily Pilocarpine HCl in Presbyopia: The Virgo Phase 3, Randomized, Double-Masked, Controlled Study.
Topics: Double-Blind Method; Humans; Pilocarpine; Presbyopia; Refraction, Ocular; Visual Acuity | 2023 |
[A study on the effects of pilocarpine in low concentration on various ophthalmic functions especially on the AC-A ratio].
Topics: Accommodation, Ocular; Adenine Nucleotides; Adult; Age Factors; Clinical Trials as Topic; Female; Hu | 1971 |
12 other studies available for pilocarpine and Presbyopia
Article | Year |
---|---|
Vuity - pilocarpine ophthalmic solution for presbyopia.
Topics: Accommodation, Ocular; Administration, Ophthalmic; Eye; Humans; Muscarinic Agonists; Ophthalmic Solu | 2022 |
Retinal Detachments Associated With Topical Pilocarpine Use for Presbyopia.
Topics: Humans; Male; Middle Aged; Miotics; Pilocarpine; Presbyopia; Retinal Detachment; Retinal Diseases; R | 2022 |
Topical Review: Pilocarpine-induced Miosis as Help for Early Presbyopes?
Topics: Accommodation, Ocular; Humans; Miosis; Ophthalmic Solutions; Pilocarpine; Presbyopia; Pupil | 2022 |
Vitreofoveal Traction Associated With Pilocarpine for Presbyopia.
Topics: Female; Humans; Pilocarpine; Presbyopia; Retinal Diseases; Tomography, Optical Coherence; Traction; | 2022 |
Pilocarpine 1.25% for the treatment of presbyopia.
Topics: Accommodation, Ocular; Humans; Lens, Crystalline; Pilocarpine; Presbyopia | 2023 |
Pilocarpine 1.25% Ophthalmic Solution (Vuity) for the Treatment of Presbyopia.
Topics: Humans; Ophthalmic Solutions; Pilocarpine; Presbyopia; Time Factors | 2023 |
Accommodation measurements in a prepresbyopic and presbyopic population.
Topics: Accommodation, Ocular; Adult; Diagnostic Techniques, Ophthalmological; Eye Color; Humans; Middle Age | 2004 |
Comparison of pilocarpine-induced and stimulus-driven accommodation in phakic eyes.
Topics: Accommodation, Ocular; Adult; Anterior Chamber; Ciliary Body; Humans; Lenses, Intraocular; Middle Ag | 2005 |
Accommodation measurements in prepresbyopic and presbyopic populations.
Topics: Accommodation, Ocular; Diagnostic Techniques, Ophthalmological; Humans; Miotics; Pilocarpine; Presby | 2005 |
Lens diameter and thickness as a function of age and pharmacologically stimulated accommodation in rhesus monkeys.
Topics: Accommodation, Ocular; Aging; Animals; Lens, Crystalline; Macaca mulatta; Miotics; Monkey Diseases; | 2008 |
Pilocarpine in the presbyope. Demonstration of an effect on the anterior chamber and lens thickness.
Topics: Aged; Anterior Chamber; Biometry; Humans; Lens, Crystalline; Middle Aged; Pilocarpine; Presbyopia; T | 1973 |
[Accommodation in presbyopics influenced by aging and extensive medication].
Topics: Accommodation, Ocular; Adult; Aging; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Piloca | 1971 |